<DOC>
	<DOCNO>NCT00609011</DOCNO>
	<brief_summary>This open-label , dose finding , multiple-dose study subject metastatic melanoma . Three dose level MPC-6827 administer temozolomide three separate cohort . Study endpoint include determination maximum tolerate dose , determination dose limit toxicity , evaluation evidence anti-tumor activity MPC-6827 give temozolomide .</brief_summary>
	<brief_title>Phase 1 Study MPC-6827 Temozolomide Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically proven melanoma For subject brain metastasis require radiation , therapy must complete least 4 week prior Day 1 Study Drug Have unresectable melanoma measurable metastasis Be minimum 4 week since prior surgical resection major surgical procedure minimum 2 week since chemotherapy/ biochemotherapy Performance score Karnofsky ≥ 60 % , Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 , WHO ≤ 2 If steroid need , stable decrease dose steroid least 1 week Hypersensitivity Cremophor EL Have current/active intratumor hemorrhage CT/MRI within 3 week prior Day 1 Study Drug confirm CT/MRI Have ocular melanoma Have primary intradural melanoma leptomeningeal involvement Have cardiovascular disease ( unstable angina MI ) Have cerebrovascular disease ( stroke and/or TIA ) Have uncontrolled hypertension Have cardiac ejection fraction &lt; 50 % Have TroponinI elevate normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic</keyword>
</DOC>